Page last updated: 2024-10-22

amifostine anhydrous and Mesothelioma

amifostine anhydrous has been researched along with Mesothelioma in 1 studies

Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.
amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.

Mesothelioma: A tumor derived from mesothelial tissue (peritoneum, pleura, pericardium). It appears as broad sheets of cells, with some regions containing spindle-shaped, sarcoma-like cells and other regions showing adenomatous patterns. Pleural mesotheliomas have been linked to exposure to asbestos. (Dorland, 27th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Zellos, L1
Richards, WG1
Capalbo, L1
Jaklitsch, MT1
Chirieac, LR1
Johnson, BE1
Bueno, R1
Sugarbaker, DJ1

Trials

1 trial available for amifostine anhydrous and Mesothelioma

ArticleYear
A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
    The Journal of thoracic and cardiovascular surgery, 2009, Volume: 137, Issue:2

    Topics: Amifostine; Antineoplastic Agents; Cisplatin; Cytoprotection; Feasibility Studies; Female; Humans; H

2009